Theodoridis A, Tsambaos D, Sivenas C, Capetanakis J
Acta Derm Venereol. 1976;56(3):253-6.
One hundred and 18 children with various clinical types of vitiligo, were treated with oral trimethylpsoralen (Trisoralen, P. B. Elder Co.) followed by exposure to sunlight or an artificial ultraviolet radiation source. In 61 of the adult patients, more than 80% of the vitiliginous areas became repigmented, 18 patients re-pigmented 50-80%, 13 repigmented less than 50% and 8 patients failed to repigment at all. In all of the children, more than 80% of the treated vitiliginous patches became repigmented. No side effects were observed. A follow-up study of the retention of the new pigment revealed that 72 adults (out of 76 followed-up) and 10 children (out of 11) without any treatment had retained 95% or more of the new pigment, 18 months after the completion of treatment. Oral trimethylpsoralen is therefore suggested for the treatment of vitiligo.
118名患有各种临床类型白癜风的儿童,接受了口服三甲补骨脂素(三甲基补骨脂素,P.B.埃尔德公司生产)治疗,随后接受阳光照射或人工紫外线辐射源照射。在61名成年患者中,超过80%的白癜风区域重新出现色素沉着,18名患者色素沉着恢复率为50%-80%,13名患者色素沉着恢复率低于50%,8名患者完全没有色素沉着恢复。在所有儿童中,超过80%接受治疗的白癜风斑块重新出现色素沉着。未观察到副作用。一项关于新色素留存情况的随访研究显示,治疗结束18个月后,76名接受随访的成年患者中有72名以及11名接受随访的儿童中有10名,在未接受任何治疗的情况下,新色素留存率达到了95%或更高。因此,建议口服三甲补骨脂素治疗白癜风。